3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
3
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Pharyngeal Neoplasms
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Erdheim-Chester Disease
1
Endometrial Adenocarcinoma
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Castleman Disease
1
Carcinoma, Transitional Cell
1
Interventions
Cyclophosphamide
13
Rituximab
11
obinutuzumab
6
fludarabine phosphate
6
Prednisone
6
Magnetic Resonance Spectroscopy
6
ibrutinib
5
fludarabine
5
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Melphalan
5
Lenalidomide
5
Etoposide
5
Doxorubicin
5
Biopsy
5
tocilizumab
4
Whole-Body Irradiation
4
venetoclax
3
polatuzumab vedotin
3
glofitamab
3
acalabrutinib
3
Vincristine
3
Mycophenolic Acid
3
Leukapheresis
3
Filgrastim
3
Cytarabine
3
Cyclosporine
3
Busulfan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
temsirolimus
×
30 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled